CURIS INC
LEXINGTON, MA · CIK 0001108205 · Biotech · Private
Small molecule HDAC/PI3K inhibitor therapeutics for cancer treatment
curis.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $964K
- 1 Form D · May 2012
- 173 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 23 granted · 17 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20112012
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $964,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2572 | AMPLION INC. | — | $1.0M |
| 2573 | Biosceptre International Ltd | — | $1.0M |
| 2574 | MATINAS BIOPHARMA, INC. | — | $1.0M |
| 2575 | CURIS INC | — | $964K |
| 2576 | SUMOCOR, LLC | — | — |
| 2577 | Thiogenesis Therapeutics, Corp. | — | $878K |
| 2578 | Gradient Pharmaceuticals, Inc. | — | $850K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Susan BayhDirector
- Michael GrayExecutive Officer
- Martyn GreenacreDirector
- Kenneth KaitinDirector
- Robert MartellDirector
- James McNab, Jr.Director
- Mark NoelExecutive Officer
- Daniel PasseriDirector · Executive Officer
- Marc RubinDirector
- James TobinDirector
- Maurizio VoiExecutive Officer
Patents
- Treating Diseases And Disorders With IRAK4-MODIFYING Compoundsapplication
- Combination Therapy With A Phosphoinositide 3-KINASE Inhibitor With A Zinc Binding Moietygranted
- Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moietyapplication
- Crystal Forms Of Immunomodulatorsapplication
- Crystal Forms Of Immunomodulatorsgranted
- Combination Therapies For The Treatment Of Cancerapplication
- Combination Therapies For The Treatment Of Cancergranted
- Conjoint Therapies For Immunomodulationgranted
- Pyridyl Inhibitors For Hedgehog Signallingapplication
- Crystal Forms Of Immunomodulatorsgranted
- Biomarkers For Fimepinostat Therapyapplication
- Methods Of Treating Diseases And Disordersapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.